Literature DB >> 15454220

Alkyl lysophosphatidic acid and fluoromethylene phosphonate analogs as metabolically-stabilized agonists for LPA receptors.

Yong Xu1, Masayuki Tanaka, Hiroyuki Arai, Junken Aoki, Glenn D Prestwich.   

Abstract

We describe an efficient method for the synthesis of alkyl lysophosphatidic acid (LPA) analogs as well as alkyl LPA mono- and difluoromethylene phosphonate analogs. Each alkyl LPA analog was evaluated for subtype-specific LPA receptor agonist activity using a cell migration assay for LPA(1) activation in cancer cells and an intracellular calcium mobilization assay for LPA(2) and LPA(3) activation. Alkyl LPAs induced pronounced cell migration activity with equivalent or higher potency than sn-1-oleoyl LPA, while the alkyl LPA fluoromethylene phosphonates proved to be less potent agonists in this assay. However, each alkyl LPA analog activated Ca(2+) release by activation of LPA(2) and LPA(3) receptors. Interestingly, the absolute configuration of the sn-2 hydroxyl group of the alkyl LPA analogs was not recognized by any of the three LPA receptors. The use of alkyl LPA analogs further expands the scope of structure-activity studies, which will better define LPA-LPA receptor interactions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15454220     DOI: 10.1016/j.bmcl.2004.08.019

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

Review 1.  Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors.

Authors:  Dong-Soon Im
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

2.  Concise synthesis of ether analogues of lysobisphosphatidic acid.

Authors:  Guowei Jiang; Yong Xu; Thomas Falguières; Jean Gruenberg; Glenn D Prestwich
Journal:  Org Lett       Date:  2005-09-01       Impact factor: 6.005

3.  Lysophosphatidic acid receptor agonists and antagonists (WO2010051053).

Authors:  Abby L Parrill
Journal:  Expert Opin Ther Pat       Date:  2011-01-11       Impact factor: 6.674

4.  Reactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells.

Authors:  Jerry A Saunders; LeAnn C Rogers; Chananat Klomsiri; Leslie B Poole; Larry W Daniel
Journal:  Free Radic Biol Med       Date:  2010-10-08       Impact factor: 7.376

5.  Functionalization of α-hydroxyphosphonates as a convenient route to N-tosyl-α-aminophosphonates.

Authors:  Tomasz Cytlak; Monika Skibińska; Patrycja Kaczmarek; Marcin Kaźmierczak; Magdalena Rapp; Maciej Kubicki; Henryk Koroniak
Journal:  RSC Adv       Date:  2018-03-27       Impact factor: 4.036

6.  Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity.

Authors:  Daniel I Benjamin; Alyssa Cozzo; Xiaodan Ji; Lindsay S Roberts; Sharon M Louie; Melinda M Mulvihill; Kunxin Luo; Daniel K Nomura
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-26       Impact factor: 11.205

Review 7.  Lysophospholipid interactions with protein targets.

Authors:  Abby L Parrill
Journal:  Biochim Biophys Acta       Date:  2008-05-02

8.  Cell type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment.

Authors:  Silke Reinartz; Sonja Lieber; Jelena Pesek; Dominique T Brandt; Alina Asafova; Florian Finkernagel; Bernard Watzer; Wolfgang Andreas Nockher; Andrea Nist; Thorsten Stiewe; Julia M Jansen; Uwe Wagner; Anne Konzer; Johannes Graumann; Robert Grosse; Thomas Worzfeld; Sabine Müller-Brüsselbach; Rolf Müller
Journal:  Mol Oncol       Date:  2018-11-15       Impact factor: 6.603

Review 9.  Plasmalogens, platelet-activating factor and beyond - Ether lipids in signaling and neurodegeneration.

Authors:  Fabian Dorninger; Sonja Forss-Petter; Isabella Wimmer; Johannes Berger
Journal:  Neurobiol Dis       Date:  2020-08-28       Impact factor: 5.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.